287 related articles for article (PubMed ID: 32801699)
21. Polymeric nanoparticles for oral delivery of 5-fluorouracil: Formulation optimization, cytotoxicity assay and pre-clinical pharmacokinetics study.
Mattos AC; Altmeyer C; Tominaga TT; Khalil NM; Mainardes RM
Eur J Pharm Sci; 2016 Mar; 84():83-91. PubMed ID: 26775869
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of magnetic nanoparticles coated by 5-fluorouracil imprinted polymer for controlled drug delivery in mouse breast cancer model.
Hashemi-Moghaddam H; Kazemi-Bagsangani S; Jamili M; Zavareh S
Int J Pharm; 2016 Jan; 497(1-2):228-38. PubMed ID: 26621688
[TBL] [Abstract][Full Text] [Related]
23. [Infusiontherapy with 5-fluorouracil ("infusional" 5-FU) in solid tumors].
Wilke H; Stahl M; Köster W; Vanhöfer U
Med Klin (Munich); 2000 Jun; 95 Suppl 1():3-8. PubMed ID: 10941246
[TBL] [Abstract][Full Text] [Related]
24. Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients.
Kline CL; Sheikh HS; Scicchitano A; Gingrich R; Beachler C; Finnberg NK; Liao J; Sivik J; El-Deiry WS
Cancer Biol Ther; 2011 Oct; 12(7):557-68. PubMed ID: 21931273
[TBL] [Abstract][Full Text] [Related]
25. [Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?].
Carnaghi C; Zucali P; Garassino I
Tumori; 2000; 86(5 Suppl 2):S19-25. PubMed ID: 11195298
[TBL] [Abstract][Full Text] [Related]
26. L-Cysteine conjugated poly L-lactide nanoparticles containing 5-fluorouracil: formulation, characterization, release and uptake by tissues in vivo.
Mishra BJ; Kaul A; Trivedi P
Drug Deliv; 2015 Feb; 22(2):214-22. PubMed ID: 24524408
[TBL] [Abstract][Full Text] [Related]
27. Oral therapy for colorectal cancer: how to choose.
Damjanov N; Meropol NJ
Oncology (Williston Park); 2000 Jun; 14(6):799-807; discussion 807-8, 813-4,. PubMed ID: 10887632
[TBL] [Abstract][Full Text] [Related]
28. Lectin-mediated cytotoxicity and specificity of 5-fluorouracil conjugated with peanut agglutinin (5-Fu-PNA) in vitro.
Cai Q; Zhang ZR
J Drug Target; 2005 May; 13(4):251-7. PubMed ID: 16051537
[TBL] [Abstract][Full Text] [Related]
29. The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients.
Scartozzi M; Sobrero A; Gasparini G; Berardi R; Catalano V; Graziano F; Barni S; Zaniboni A; Beretta GD; Labianca R; Cascinu S;
Oncology; 2005; 68(2-3):212-6. PubMed ID: 16015036
[TBL] [Abstract][Full Text] [Related]
30. Development of a 5-fluorouracil-loaded PLGA microsphere delivery system by a solid-in-oil-in-hydrophilic oil (S/O/hO) novel method for the treatment of tumors.
Lin Q; Cai Y; Yuan M; Ma L; Qiu M; Su J
Oncol Rep; 2014 Dec; 32(6):2405-10. PubMed ID: 25231485
[TBL] [Abstract][Full Text] [Related]
31. Green encapsulation of LDH(Zn/Al)-5-Fu with carboxymethyl cellulose biopolymer; new nanovehicle for oral colorectal cancer treatment.
Pooresmaeil M; Behzadi Nia S; Namazi H
Int J Biol Macromol; 2019 Oct; 139():994-1001. PubMed ID: 31401278
[TBL] [Abstract][Full Text] [Related]
32. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
[TBL] [Abstract][Full Text] [Related]
33. Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases.
Kusunoki M; Yanagi H; Noda M; Yoshikawa R; Yamamura T
Cancer; 2000 Sep; 89(6):1228-35. PubMed ID: 11002217
[TBL] [Abstract][Full Text] [Related]
34. Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells.
Murakami Y; Kazuno H; Emura T; Tsujimoto H; Suzuki N; Fukushima M
Int J Oncol; 2000 Aug; 17(2):277-83. PubMed ID: 10891536
[TBL] [Abstract][Full Text] [Related]
35. Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer.
Kuebler JP; de Gramont A
Semin Oncol; 2003 Aug; 30(4 Suppl 15):40-6. PubMed ID: 14523794
[TBL] [Abstract][Full Text] [Related]
36. Pharmacodynamics induced by direct electric current for the treatment of 5-fluorouracil resistant tumor: an animal experiment.
Ito K; Wong L; Ando H; Hibi K; Hidemura K; Kasai Y; Akiyama S; Nakao A
Int J Colorectal Dis; 2001 Sep; 16(5):326-30. PubMed ID: 11686532
[TBL] [Abstract][Full Text] [Related]
37. 5-Fluorouracil derivatives: a patent review.
Álvarez P; Marchal JA; Boulaiz H; Carrillo E; Vélez C; Rodríguez-Serrano F; Melguizo C; Prados J; Madeddu R; Aranega A
Expert Opin Ther Pat; 2012 Feb; 22(2):107-23. PubMed ID: 22329541
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-149 Increases the Sensitivity of Colorectal Cancer Cells to 5-Fluorouracil by Targeting Forkhead Box Transcription Factor FOXM1.
Liu X; Xie T; Mao X; Xue L; Chu X; Chen L
Cell Physiol Biochem; 2016; 39(2):617-29. PubMed ID: 27415661
[TBL] [Abstract][Full Text] [Related]
39. Overcoming multidrug resistance in 2D and 3D culture models by controlled drug chitosan-graft poly(caprolactone)-based nanoparticles.
Shi WB; Le VM; Gu CH; Zheng YH; Lang MD; Lu YH; Liu JW
J Pharm Sci; 2014 Apr; 103(4):1064-74. PubMed ID: 24523221
[TBL] [Abstract][Full Text] [Related]
40. [Concentrations of 5-fluorouracil (5-FU) in serum and tissues at venous injection of tegafur or 5-FU--clinical study on colorectal cancer].
Kojima T; Suzumura K; Kanemitsu T; Miyashita A; Inamura Y; Owa Y; Naruse T
Gan To Kagaku Ryoho; 1998 Mar; 25(4):547-51. PubMed ID: 9530361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
